AstraZeneca which is the UK 2nd biggest drug developer is currently looking for new products, acquiring Ardea also means that Astra Zeneca gains a drug called Lesinurad,
Ardea, California-based biotechnology company focused on the development of small-molecule therapeutics. Ardea’s top drug Lesinurad is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout. This disease is expected to affect almost 17 million people by 2019.
David Brennan, AstraZeneca’s chief executive, said: This attractive Phase III programme is an excellent opportunity to leverage AstraZeneca’s global specialty and primary care sales and marketing capabilities…..The Ardea team has done a great job developing Lesinurad along with a promising next-generation gout programme. These compounds have real potential to benefit patients.”
Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates